Is There a Lawsuit Against Depo-Provera? Who Qualifies and Where the Settlement Stands
Yes. Thousands of women have sued Pfizer alleging that repeated Depo-Provera (medroxyprogesterone acetate) injections were linked to intracranial meningioma brain tumors and that the product did not carry an adequate warning during the years they used it.
Federal cases are consolidated in MDL 3140 in the Northern District of Florida, and in June 2026 the parties reported a global agreement in principle to resolve eligible meningioma claims. A claim is generally worth reviewing when documented injections came before a confirmed meningioma diagnosis.
Find Out If You Qualify for the Depo-Provera Lawsuit
Use the short form for a confidential review of your injections, diagnosis, treatment, symptoms and losses.
What the Depo-Provera Lawsuit Claims
Depo-Provera is a contraceptive injection made with medroxyprogesterone acetate. The lawsuits claim that repeated injections were associated with intracranial meningioma and that the warnings available during the relevant years were not adequate. Pfizer disputes liability and has raised defenses on causation, preemption, product identification, timing and other issues.
This is not a class action that pays everyone the same amount. Each woman must show she used the product, was diagnosed, and that the injury, damages and deadline requirements are met. The MDL handles shared pretrial issues while keeping each case individual.
Who Qualifies for the Depo-Provera Lawsuit?
Screening criteria can change as the settlement program is implemented. A claim is usually worth a closer look when several of these apply:
- Records showing Depo-Provera or another depot medroxyprogesterone acetate injection.
- Repeated or long-term injections before the diagnosis.
- A confirmed intracranial meningioma diagnosis.
- Treatment such as a craniotomy, radiation, medication, rehabilitation or ongoing monitoring.
- Neurological symptoms, disability, lost income, medical bills or reduced quality of life.
- A filing deadline that has not yet passed under the law that applies to you.
Be cautious of any website claiming a single minimum number of shots qualifies everyone. Eligibility depends on your records and the program's criteria, which should be confirmed by an attorney.
MDL 3140 and the Settlement: Where Things Stand
The Judicial Panel on Multidistrict Litigation consolidated federal Depo-Provera product liability cases in the Northern District of Florida on February 7, 2025, before Judge M. Casey Rodgers (master docket 3:25-md-3140). On June 15, 2026, plaintiffs' leadership and Pfizer told the court they had reached a global agreement in principle to resolve eligible meningioma claims, and a Master Settlement Agreement followed in July 2026.
March 2024: BMJ Study
A national case-control study reported an association between long-term injectable medroxyprogesterone acetate and meningioma requiring surgery.
February 2025: MDL Formed
The JPML sent federal cases to the Northern District of Florida for coordinated pretrial proceedings.
December 2025: FDA Label Change
The FDA approved meningioma risk language in the U.S. prescribing information.
June to September 2026: Settlement Framework
Bellwether trial deadlines were vacated after the agreement in principle, a settlement administrator and allocation master were appointed, and plaintiffs who do not participate face separate case requirements. Court orders are the best source for exact deadlines.
What Affects a Depo-Provera Claim's Value
Payment tiers and individual amounts under the settlement had not been made public as of this update, so any dollar figure you see online is an estimate, not a confirmed average. Value is expected to turn on tumor grade and location, surgery, radiation, permanent deficits, recurrence, future care, age, lost income, caregiving needs, proof of use and causation evidence.
| Injury Level (Educational) | Common Characteristics | What Usually Matters Most |
|---|---|---|
| Most serious claims | Craniotomy, recurrence, major neurological deficits, significant disability or death. | Surgery and pathology, permanent impairment, future care, lost earnings, dependents and strong proof of use. |
| Moderate-to-severe review | Radiation, significant symptoms, substantial treatment, work limits or ongoing neurological care. | Treatment burden, symptoms, medical bills, lost income, prognosis and day-to-day impact. |
| Monitoring or lower-damage claims | A confirmed meningioma managed with scans, limited symptoms or no surgery so far. | Tumor size and location, monitoring burden, symptoms, future risk and causation evidence. |
What the Research Says About Depo-Provera and Meningioma
A 2024 national case-control study in The BMJ found an association between prolonged use of injectable medroxyprogesterone acetate and meningioma requiring surgery, with a reported odds ratio of about 5.6 for prolonged use. Because it was observational, the study showed an association, not proof that the drug caused any particular tumor.
Research has continued since then. Whether the drug caused a specific person's tumor still depends on how long and when she used it, other risk factors, imaging, pathology, treatment and expert analysis.
Proof of Injections
Pharmacy records, clinic notes, OB/GYN files and injection logs can show what you received and for how long.
Confirmed Meningioma
MRI and CT reports, surgical notes, pathology, radiation records and neurosurgery reports document the tumor and treatment.
Use Before Diagnosis
When and how long you used Depo-Provera compared with when the tumor was found is central to every review.
The FDA's Meningioma Label Change
In December 2025 the FDA approved updated prescribing information adding meningioma risk language to the warnings and precautions for Depo-Provera CI and depo-subQ provera 104. The label says meningiomas have been reported after repeated use, mainly long-term use, and tells clinicians to stop the drug if a meningioma is diagnosed.
Note: The meningioma language is in the warnings and precautions section, not the boxed warning, which concerns loss of bone mineral density.
What Is a Meningioma?
A meningioma grows from the meninges, the layers of tissue around the brain and spinal cord. Most are not cancerous, but their size and location can still cause serious neurological problems and require major treatment.
Possible Symptoms
Headaches, seizures, changes in vision or hearing, weakness, memory trouble, balance problems or personality changes.
Diagnosis
Usually found on MRI or CT; pathology after surgery can confirm the type and grade.
Treatment
Monitoring, surgery, radiation, medication, rehabilitation or a combination, depending on the tumor.
Long-Term Impact
Some patients face recurrence, lasting deficits, lower earning ability, ongoing scans or future care.
Records That Support a Depo-Provera Claim
Proof You Received the Shots
Pharmacy and insurance records, clinic injection logs, Planned Parenthood and OB/GYN records, and prescriber notes.
Medical Evidence
Imaging reports, pathology, surgical and radiation records, neurology and neurosurgery notes, medications and rehab records.
Damages Evidence
Medical bills, pay records, disability paperwork, travel and caregiving costs, symptom journals and proof of daily limitations.
How a Depo-Provera Claim Moves Forward
- Screening: Product use, diagnosis, treatment, dates, venue and deadlines.
- Records: Injection, pharmacy, imaging, pathology, surgery, radiation, income and damages records.
- Legal and medical review: Product identification, causation, warnings, damages and the law that applies.
- Filing and registration: A retained attorney files the case or registers it in the settlement program and handles MDL requirements.
- Settlement review or litigation: Eligible claims go through the settlement process; others proceed under the court's orders.
- Outcome: A claim may be paid through the program, settled separately, tried or dismissed. Nothing is guaranteed.
Deadlines for Depo-Provera Claims
Statutes of limitations differ by state and can depend on when you were diagnosed, when you learned of a possible link, where you lived or received injections and other facts. A one-size "two to four years" rule is not reliable.
The settlement program also has its own registration deadlines. Missing either type of deadline can end a claim, so get a state-specific review now rather than waiting.
Depo-Provera Lawsuit Questions
Is there a Depo-Provera class action?
No. Federal cases are coordinated in MDL 3140, where each woman keeps her own claim and must prove her own use, injury, causation, damages and deadlines.
Has the Depo-Provera lawsuit settled?
A global agreement in principle was reported in June 2026 and a Master Settlement Agreement followed in July 2026 for eligible meningioma claims. Payment tiers and individual amounts had not been published as of this update.
What diagnosis is the lawsuit about?
Intracranial meningioma following depot medroxyprogesterone acetate use.
How much could a Depo-Provera claim be worth?
It depends on treatment, surgery, neurological deficits, recurrence, future care, lost income, age, proof of use and causation evidence, and on how the settlement's allocation rules treat those factors.
What records prove I received Depo-Provera?
Pharmacy and insurance claims, clinic injection logs, OB/GYN and Planned Parenthood records, and prescriber notes.
Should I stop Depo-Provera on my own?
No. Talk to a licensed healthcare provider about contraception and treatment. The FDA label says the drug should be stopped if a meningioma is diagnosed.
My shots came from a clinic. Does that matter?
Clinic records can be strong proof of use. Product liability claims generally focus on the manufacturer, but the right defendants depend on the facts and law.
How soon should I get my claim reviewed?
Right away. State deadlines and settlement registration dates both apply, and waiting can put a claim at risk.
Sources
Each source supports the statement nearest to it. Litigation and settlement details change, so check court orders and agency documents for exact dates and counts.
- U.S. District Court, Northern District of Florida: Depo-Provera MDL 3140. Official case page and master docket. Accessed October 9, 2026.
- JPML MDL 3140 Transfer Order. February 7, 2025 consolidation order. Accessed October 9, 2026.
- FDA-approved Depo-Provera CI and depo-subQ provera 104 prescribing information, including meningioma warnings. Accessed October 9, 2026.
- FDA supplement approval letter, December 12, 2025. Accessed October 9, 2026.
- Roland N, et al. Use of progestogens and the risk of intracranial meningioma. The BMJ, 2024. Accessed October 9, 2026.
- PubMed record for the 2024 case-control study. Accessed October 9, 2026.
Ask for a Confidential Depo-Provera Review
Use the form above or call to discuss your injections, diagnosis, treatment, records, deadlines and options.
